Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 22 | 2021Cilta-cel’s MAA Not Submitted; No Regulatory Updates for Liso-cel and Ide-cel; CHMP March AgendaAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA Mar 18 | 2021Cilta-cel’s Japanese BLA Submission Anticipated for H2 2021; CARTITUDE-1 and CARTITUDE-2 Clinical Updates Expected in 2021; No Major Updates for Precision BioSciences; Legend and Precision Q4 2020 Earnings Call SummariesAccess Free BlastFree
Posted in: Autologous, CAR-T Mar 17 | 2021Gilead (Kite) Partners with COTA to Accelerate Clinical Development Using Real-World DataAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 16 | 2021Thoughts on Autolus's New Dual BCMA x CD19 CAR-T Ph1 Trial in Multiple MyelomaAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Mar 12 | 2021Thoughts on Kymriah's Approval in Singapore; Could Singapore Become a Hub for Cell Therapy Medical Tourism in Southeast Asia?Access Free BlastFree
Posted in: CAR-T, CD19, TCR Mar 11 | 2021No Major Updates Presented at Ziopharm’s R&D DayAccess Free BlastFree
Posted in: Autologous, CAR-T Mar 10 | 2021New Gilead KITE-222 (CLL-1 CAR-T) Ph1 Trial in R/R AML PostedAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Mar 09 | 2021Yescarta Receives Broader FL Label Than Breyanzi; MZL Not Granted in Yescarta's ZUMA-5 Accelerated ApprovalAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD123, CD22, CS1 Mar 05 | 2021Cellectis Anticipates Submitting Multiple Undisclosed INDs Within 12 Months; No Clinical Updates for 3 UCART Programs; Cellectis Q4 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22 Mar 04 | 2021Five New Autolus CAR-T Products to Enter the Clinic in 2021; AUTO1’s ALL Market Opportunity; Autolus Q4 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Mar 03 | 2021New Academic CD19 CAR-T ARI-0001 Ph2 Trial in R/R ALL PostedAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD123, CD19, CD22, CS1 Mar 02 | 2021Thoughts on Heidi Hagen’s Appointment as Interim Ziopharm CEO; Allogene Anticipates Two New Clinical Trials in 2021; Ziopharm and Allogene Q4 2020 Earnings Call SummariesAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 26 | 2021Ide-cel Reverts to Standard Assessment; Liso-cel’s Potential Scenarios for Approval; CHMP February Agenda and HighlightsAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T Feb 25 | 2021Thoughts on Poseida’s Strategies to Improve Allogeneic CAR-T Manufacturing and Efficacy; Clinical Development Updates and New Cell Therapy Platforms; Poseida’s First R&D Day SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 24 | 2021BMS's New US Cell Therapy Manufacturing Site; bluebird bio Quiet on Earnings; Former Kite Head of Development Joins Daiichi SankyoAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR Feb 22 | 2021CAR-TCR European Summit Round-Up: Cellectis-Cytovia Partnership; JNJ's (Janssen) Thoughts on EU CAR-T Reimbursement; Strategies to Improve CAR-T FitnessAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 19 | 2021Yescarta's Median Time to CRS Improved by Prophylactic Corticosteroid Use; Thoughts on Frank Neumann Joining Kite as Worldwide Head of Clinical DevelopmentAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 15 | 2021Kymriah’s First Commercial Manufacturing Facility Approved in Australia; Novartis Increases Manufacturing Footprint to Six Global CentersAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 11 | 2021Spain Approves the First Potentially Low-Cost Academically Manufactured CD19 CAR-T for Adult ALL Patients; Could EMA Approval be Next?Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 08 | 2021Thoughts on Breyanzi’s (liso-cel) Label, Price, Manufacturing, and TAT Compared to Kymriah and YescartaAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.